Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

928 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Multicenter Prospective Study in HER2-Positive Early Breast Cancer for Detecting Minimal Residual Disease by Circulating Tumor DNA Analysis With Neoadjuvant Chemotherapy: HARMONY Study.
Tokura M, Ando MM, Kojima Y, Kitadai R, Yazaki S, Atutubo CMN, Li RK, Perez MZ, Gorospe AE, Madrid MA, Ordinario MVC, Imasa MSB, Sudo K, Shimoi T, Suto A, Kohsaka S, Machida R, Sadachi R, Yoshida M, Yatabe Y, Hata T, Nakamura K, Yonemori K, Shiino S. Tokura M, et al. Among authors: sudo k. Breast Cancer (Auckl). 2024 Oct 27;18:11782234241288671. doi: 10.1177/11782234241288671. eCollection 2024. Breast Cancer (Auckl). 2024. PMID: 39493594 Free PMC article.
Integrative prognostic analysis of tumor-infiltrating lymphocytes, CD8, CD20, programmed cell death-ligand 1, and tertiary lymphoid structures in patients with early-stage triple-negative breast cancer who did not receive adjuvant chemotherapy.
Yazaki S, Shimoi T, Yoshida M, Sumiyoshi-Okuma H, Arakaki M, Saito A, Kita S, Yamamoto K, Kojima Y, Nishikawa T, Tanioka M, Sudo K, Noguchi E, Murata T, Shiino S, Takayama S, Suto A, Ohe Y, Fujiwara Y, Yonemori K. Yazaki S, et al. Among authors: sudo k. Breast Cancer Res Treat. 2023 Jan;197(2):287-297. doi: 10.1007/s10549-022-06787-x. Epub 2022 Nov 16. Breast Cancer Res Treat. 2023. PMID: 36385236 Free PMC article.
A multicenter investigator-initiated Phase 2 trial of E7090 in patients with advanced or recurrent solid tumor with fibroblast growth factor receptor (FGFR) gene alteration: FORTUNE trial.
Chiba Y, Sudo K, Kojima Y, Okuma H, Kohsaka S, Machida R, Ichimura M, Anjo K, Kurishita K, Okita N, Nakamura K, Kinoshita I, Takahashi M, Matsubara J, Kusaba H, Yonemori K, Takahashi M. Chiba Y, et al. Among authors: sudo k. BMC Cancer. 2022 Aug 9;22(1):869. doi: 10.1186/s12885-022-09949-8. BMC Cancer. 2022. PMID: 35945547 Free PMC article. Clinical Trial.
Impact of adjuvant chemotherapy and radiotherapy on tumour-infiltrating lymphocytes and PD-L1 expression in metastatic breast cancer.
Yazaki S, Salgado R, Shimoi T, Yoshida M, Shiino S, Kaneda T, Kojima Y, Sumiyoshi-Okuma H, Nishikawa T, Sudo K, Noguchi E, Murata T, Takayama S, Suto A, Ohe Y, Yonemori K. Yazaki S, et al. Among authors: sudo k. Br J Cancer. 2023 Feb;128(4):568-575. doi: 10.1038/s41416-022-02072-2. Epub 2022 Dec 15. Br J Cancer. 2023. PMID: 36522476 Free PMC article.
Low HER2 expression is a predictor of poor prognosis in stage I triple-negative breast cancer.
Sanomachi T, Okuma HS, Kitadai R, Kawachi A, Yazaki S, Tokura M, Arakaki M, Saito A, Kita S, Yamamoto K, Maejima A, Kojima Y, Nishikawa T, Sudo K, Shimoi T, Noguchi E, Fujiwara Y, Sugino H, Shiino S, Suto A, Yoshida M, Yonemori K. Sanomachi T, et al. Among authors: sudo k. Front Oncol. 2023 Mar 27;13:1157789. doi: 10.3389/fonc.2023.1157789. eCollection 2023. Front Oncol. 2023. PMID: 37051545 Free PMC article.
Clinicopathological and prognostic features of HER2-null and HER2-low advanced breast cancer treated with eribulin or capecitabine.
Kitadai R, Shimoi T, Yazaki S, Okuma HS, Hoshino M, Ito M, Saito A, Kita S, Kojima Y, Nishikawa T, Sudo K, Noguchi E, Fujiwara Y, Yoshida M, Yonemori K. Kitadai R, et al. Among authors: sudo k. Breast Cancer. 2024 Nov;31(6):1037-1045. doi: 10.1007/s12282-024-01617-y. Epub 2024 Aug 14. Breast Cancer. 2024. PMID: 39141076 Free PMC article.
Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population.
Noda-Narita S, Shimomura A, Kawachi A, Sumiyoshi-Okuma H, Sudo K, Shimoi T, Noguchi E, Yonemori K, Shimizu C, Fujiwara Y, Tamura K. Noda-Narita S, et al. Among authors: sudo k. Breast Cancer. 2019 Jul;26(4):492-498. doi: 10.1007/s12282-019-00949-4. Epub 2019 Feb 8. Breast Cancer. 2019. PMID: 30737616 Free PMC article.
Survival outcomes in patients with human epidermal growth factor receptor 2 positive metastatic breast cancer administered a therapy following trastuzumab emtansine treatment.
Watanuki R, Shimomura A, Yazaki S, Noda-Narita S, Sumiyoshi-Okuma H, Nishikawa T, Tanioka M, Sudo K, Shimoi T, Noguchi E, Yonemori K, Tamura K. Watanuki R, et al. Among authors: sudo k. Medicine (Baltimore). 2020 Sep 18;99(38):e22331. doi: 10.1097/MD.0000000000022331. Medicine (Baltimore). 2020. PMID: 32957402 Free PMC article.
Hotspot mutation profiles of AKT1 in Asian women with breast and endometrial cancers.
Shimoi T, Hashimoto J, Sudo K, Shimomura A, Noguchi E, Shimizu C, Yunokawa M, Yonemori K, Yoshida H, Yoshida M, Kato T, Kinoshita T, Fukuda T, Fujiwara Y, Tamura K. Shimoi T, et al. Among authors: sudo k. BMC Cancer. 2021 Oct 21;21(1):1131. doi: 10.1186/s12885-021-08869-3. BMC Cancer. 2021. PMID: 34670536 Free PMC article.
928 results